Randomized trial · people

Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesity

Checked against the paper Randomized trialPublished by PepVault

The takeaway

For obesity caused by hypothalamic damage, this year-long placebo-controlled trial adds evidence that setmelanotide lowered BMI and hunger, with more side effects, including serious ones, than placebo.

Kind
Randomized trial
Studied in
People
Number studied
120
Published
2026
Journal
N Engl J Med

What they tested

The team tested whether daily setmelanotide lowers BMI and hunger more than placebo in people whose obesity followed a hypothalamic tumor, lesion or injury.

How the study was done

A phase 3, randomized, placebo-controlled trial in 120 people aged 4 to 66 with acquired hypothalamic obesity: 81 got setmelanotide and 39 got placebo (a dummy shot), given once daily under the skin. Treatment ran for 52 weeks after a dose-escalation period, with trial doses of 1.5 to 3.0 mg.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

BMI (body-mass index, weight relative to height) changed by -16.5% on setmelanotide and by 3.3% on placebo at 52 weeks (P<0.001). In participants aged 12 and older, the weekly average of peak daily hunger, scored 0 to 10, fell by 2.73 points on setmelanotide and by 1.45 points on placebo (P = 0.009). Adverse events occurred in 100% of the setmelanotide group and 90% of the placebo group, and serious adverse events in 28% and 8%. The most common side effects on setmelanotide were skin darkening (hyperpigmentation), nausea, vomiting and headache.

What it doesn’t show

The trial lasted 52 weeks and included only people with obesity after hypothalamic damage, so it does not show longer-term effects or results in other kinds of obesity. Hunger was measured only in those aged 12 and older, and the trial was funded by Rhythm Pharmaceuticals.

The paper

Miller et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med. 2026.

The compound

More studies on Setmelanotide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking setmelanotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo